【摘要】 目的:探究达比加群酯治疗妇科恶性肿瘤合并下肢深静脉血栓患者的安全性、有效性及长期抗凝的依从性。方法:选取27例妇科恶性肿瘤合并下肢深静脉血栓的患者作为研究对象，按照治疗方式不同将患者分为实验组(n=15)和对照组(n=12):对照组采用低分子肝素标准治疗剂量抗凝；实验组采用达比加群酯口服150 mg, 2次/d抗凝，疗程3个月。分别于治疗前及治疗后1 d、1周、2周及1、2、3个月测量下肢周径、血清D-二聚体、凝血功能、血常规及肝肾功能，评估并比较两组患者临床症状及方便性、依从性，分析治疗前后两组患者双下肢血栓及临床指标改善情况。结果:两组患者健、患侧肢体大、小腿周径差、血常规指标、肝肾功指标、D-二聚体在治疗后1 d、1周、2周及1、2、3个月差异均无统计学意义(P>0.05);凝血功能(TT)在治疗后1 d、1周、2周及1、2、3个月差异有统计学意义(P<0.05);在治疗后3个月，对照组有2例血栓复发，实验组无血栓复发，差异无统计学意义(P>0.05);实验组治疗简便性、依从性量化评分高于对照组，差异有统计学意义(P<0.05)。结论:达比加群对于妇科恶性肿瘤合并下肢深静脉血栓形成患者具有良好的安全性、有效性以及服药依从性。更多还原

【Abstract】 Objective:To explore the safety, efficacy, and compliance of long-term anticoagulation with dabigatran in patients with gynecologic malignancies complicated by lower extremity deep venous thrombosis(DVT).Methods:A total of 27 patients with gynecologic malignancies and lower extremity DVT were divided into an experimental group and a control group.The control group(12 cases) received standard therapeutic doses of low-molecular-weight heparin for anticoagulation.The experimental group(15 cases) received oral dabigatran at a dose of 150 mg twice daily for 3 months.The circumference of the lower extremities, serum D-dimer levels, coagulation function, complete blood count, and liver and kidney function were measured before and 1 day, 1 week, 2 weeks, 1 month, 2 months and 3 months after treatment.Clinical symptoms were evaluated, and patients filled out convenience and compliance questionnaires.The improvement of bilateral lower extremity thrombosis and clinical indicators before and after treatment were analyzed.Results:There was no significant difference between the two groups of patients in terms of healthy and affected limb size, leg circumference difference, blood routine, liver and kidney function, and D-dimer at 1 day, 1 week, 2 weeks, 1 month, 2 month and 3 months after treatment(P>0.05).There was a significant difference in coagulation function(TT) at 1 day, 1 week, 2 weeks, 1 month, 2 months and 3 months after treatment(P<0.05).3 month after treatment, there were 2 cases of thrombus recurrence in the control group and 0 case in the experimental group, with no significant difference(P>0.05).The quantitative scores of treatment convenience and compliance in the experimental group were higher than those in the control group, and the difference was statistically significant(P<0.05).Conclusion:Dabigatran has good safety, efficacy and medication compliance in the treatment of lower extremity DVT in patients with gynecologic malignancies.更多还原